Yisheng Pharmaceutical released its 2026 interim report. The company's total operating revenue was 338 million yuan, net profit attributable to the parent company was 26.8311 million yuan, and net cash inflow from operating activities was 40.0734 million yuan. The company's latest asset-liability ratio was 22.16 percent, up 0.18 percentage points from the previous quarter. Gross margin was 75.18 percent, return on equity was 1.20 percent, and diluted earnings per share was 0.08 yuan. The company's latest total asset turnover was 0.11 times, inventory turnover was 0.05 times, and the number of shareholders was 19,300. The top ten shareholders held 160 million shares, accounting for 48.32 percent of total share capital.
Jilin Jian Yisheng Pharmaceutical Co LtdInterim report shows modest net profit and financial metrics, but no comparative context or market reaction provided.
